Human health risk assessment for peroxisome proliferators: More than 30 years of research

Experimental and Toxicologic Pathology

Volumn 61, Issue 3, 2009, Pages 215-221

  Fidaleo, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Cell proliferation; Hepatocarcinogenesis; Oxidative stress; Peroxisome proliferator (PP); Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

CIPROFIBRATE; FIBRIC ACID DERIVATIVE; MESSENGER RNA; NAFENOPIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID;

APOPTOSIS; CELL PROLIFERATION; GENE; HEALTH HAZARD; HUMAN; KUPFFER CELL; LIVER CARCINOGENESIS; LIVER CELL; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK ASSESSMENT; RODENT;

ANIMALS; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; PEROXISOME PROLIFERATORS; PPAR ALPHA; RATS; RISK ASSESSMENT; SPECIES SPECIFICITY;

RODENTIA;

EID: 64749094518     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2008.09.002     Document Type: Review

References (68)

1. Albi E., Pieroni S., Viola Magni M.P., and Sartori C. Chromatin sphingomyelin changes in cell proliferation and/or apoptosis induced by ciprofibrate. J Cell Physiol 196 (2003) 354-361
2. Albi E., Cataldi S., Viola Magni M.P., and Sartori C. Plasmalogens in rat liver chromatin: new molecules involved in cell proliferation. J Cell Physiol 201 (2004) 439-446
3. Auwerx J., Schoonjans K., Fruchart J.C., and Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124 (1996) S29-S37
4. Blümcke S., Schwartzkopff W., Lobeck H., Edmondson N.A., Prentice D.E., and Blane G.F. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis 46 (1983) 105-116
5. Cattley R.C. Peroxisome proliferators and receptor-mediated hepatic carcinogenesis. Toxicol Pathol 32 (2004) 6-11
6. Cattley R.C., DeLuca J., Elcombe C., Fenner-Crisp P., Lake B.G., Marsman D.S., et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?. Regul Toxicol Pharmacol 27 (1998) 47-60
7. Choudhury A.I., Chahal S., Bell A.R., Tomlinson S.R., Roberts R.A., Salter A.M., et al. Species differences in peroxisome proliferation; mechanisms and relevance. Mutat Res 448 (2000) 201-212
8. Christensen J.G., Gonzales A.J., Cattley R.C., and Goldsworthy T.L. Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens. Cell Growth Differ 9 (1998) 815-825
9. Cosulich S.C., and Roberts R.A. Peroxisome proliferators require p38 RK activity to suppress apoptosis and induce S-phase in rat primary hepatocytes. Proc Am Assoc Cancer Res 40 (1999) 741
10. Cosulich S.C., James N.H., Needham M.R., Newham P.P., Bundell K.R., and Roberts R.A. A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopin. Carcinogenesis 21 (2000) 1757-1760
11. De La Iglesia F.A., Lewis J.E., Buchanan R.A., Marcus E.L., and McMahon G. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43 (1982) 19-37
12. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
13. Doull J., Cattley R., Elcombe C., Lake B.G., Swenberg J., Wilkinson C., et al. Cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new US EPA risk assessment guidelines. Regul Toxicol Pharmacol 29 (1999) 327-357
14. Feige J.N., Gelman L., Michalik L., Desvergne B., and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45 (2006) 120-159
15. Gariot P., Barrat E., Drouin P., Genton P., Pointel J.P., Foliguet B., et al. Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism 36 (1987) 203-210
16. Goll V., Alexandre E., Viollon-Abadie C., Nicod L., Jaeck D., and Richert L. Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. Toxicol Appl Pharmacol 160 (1999) 21-32
17. Gonzalez F.J., and Shah Y.M. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246 (2008) 2-8
18. Hahn S.E., and Goldberg D.M. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 43 (1992) 625-633
19. Hasmall S.C., West D.A., Olsen K., and Roberts R.A. Role of hepatic non-parenchymal cells in the response of rat hepatocytes to the peroxisome proliferator nafenopin in vitro. Carcinogenesis 21 (2000) 2159-2165
20. Hess R., Staubli W., and Reiss W. Nature of the hepatomegalic effect produced by ethyl-chlorphenoxyisobutyrate in the rat. Nature 208 (1965) 856-858
21. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
22. Issemann I., Prince R.A., Tugwood J.D., and Green S. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 11 (1993) 37-47
23. James N.H., and Roberts R.A. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 17 (1996) 1623-1632
24. Jin F.Y., Kamanna V.S., Chuang M.Y., Morgan K., and Kashyap M.L. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler Thromb Vasc Biol 16 (1996) 1052-1062
25. Kamendulis L.M., Isenberg J.S., Smith J.H., Pugh Jr. G., Lington A.W., and Klaunig J.E. Comparative effects of phthalate monoesters on gap junctional intercellular communication and peroxisome proliferation in rodent and primate hepatocytes. J Toxicol Environ Health A 65 (2002) 569-588
26. Lake B.G. Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. Toxicol Lett 82-83 (1995) 673-681
27. Lake B.G., Rumsby P.C., Price R.J., and Cunninghame M.E. Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-beta1 gene expression in the rat, Syrian hamster and guinea pig. Mutat Res 448 (2000) 213-225
28. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., et al. Targeted disruption of the isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022
29. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272 (1997) 3406-3410
30. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
31. Mounho B.J., and Thrall B.D. The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. Toxicol Appl Pharmacol 159 (1999) 125-133
32. Oberhammer F., Fritsch G., Pavelka M., Froschl G., Tiefenbacher R., Purchio T., et al. Induction of apoptosis in cultured hepatocytes and in the regressing liver by transforming growth factor-beta 1 occurs without activation of an endonuclease. Toxicol Lett 64-65 (1992) 701-704
33. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., and Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53 (1998) 14-22
34. Perrone C.E., Shao L., and Williams G.M. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 150 (1998) 277-286
35. Peters J.M., Cattley R.C., and Gonzalez F.J. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18 (1997) 2029-2033
36. Peters J.M., Cheung C., and Gonzalez F.J. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?. J Mol Med 83 (2005) 774-785
37. Reddy J.K. Peroxisome proliferators and peroxisome proliferator-activated receptor alpha: biotic and xenobiotic sensing. Am J Pathol 164 (2004) 2305-2321
38. Reddy J.K., and Chu R. Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon. Ann N Y Acad Sci 804 (1996) 176-201
39. Reddy J.K., and Krishnakantha T.P. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science 190 (1975) 787-789
40. Reddy J.K., and Lalwani N.D. Carcinogenesis by hepatic peroxisome proliferators. Evaluations of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit Rev Toxicol 12 (1983) 1-58
41. Reddy J.K., and Rao M.S. Xenobiotic-induced peroxisome proliferation: role of tissue specificity and species differences in response in the evaluation of the implications for human health. Arch Toxicol Suppl 10 (1987) 43-53
42. Reddy J.K., Azarnoff D.L., and Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283 (1980) 397-398
43. Roberts R., and Moffat G. Biology and toxicology of PPAR alpha ligands - the hypolipidaemic peroxisome proliferatiors. Comments Toxicol 7 (2001) 259-274
44. Roberts R.A., Soames A.R., Gill J.H., James N.H., and Wheeldon E.B. Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis 16 (1995) 1693-1698
45. Roberts R.A., James N.H., Woodyatt N.J., Macdonald N., and Tugwood J.D. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 19 (1998) 43-48
46. Roberts R.A., Ganey P.E., Ju C., Kamendulis L.M., Rusyn I., and Klaunig J.E. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 96 (2007) 2-15
47. Roglans N., Bellido A., Rodríguez C., Cabrero A., Novell F., Ros E., et al. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther 72 (2002) 692-701
48. Rolfe M., James N.H., and Roberts R.A. Tumour necrosis factor alpha (TNF alpha) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators?. Carcinogenesis 18 (1997) 2277-2280
49. Rose M.L., Rusyn I., Bojes H.K., Belyea J., Cattley R.C., and Thurman R.G. Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat Res 448 (2000) 179-192
50. Rusyn I., Asakura S., Pachkowski B., Bradford B.U., Denissenko M.F., Peters J.M., et al. Expression of base excision DNA repair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular source of radicals responsible for DNA damage by peroxisome proliferators. Cancer Res 64 (2004) 1050-1057
51. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., and Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6 (1992) 1634-1641
52. Schrader M., and Fahimi H.D. Peroxisomes and oxidative stress. Biochim Biophys Acta 1763 (2006) 1755-1766
53. Shah Y.M., Morimura K., Yang Q., Tanabe T., Takagi M., and Gonzalez F. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 27 (2007) 4238-4247
54. Sher T., Yi H.F., McBride O.W., and Gonzalez F.J. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32 (1993) 5598-5604
55. Staels B., and Auwerx J. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. Development 115 (1992) 1035-1043
56. Staels B., Schoonjans K., Fruchart J.C., and Auwerx J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie 79 (1997) 95-99
57. Takagi A., Sai K., Umemura T., Hasegawa R., and Kurokawa Y. Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate. Cancer Lett 53 (1990) 33-38
58. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8 (1994) 1224-1234
59. Trosko J.E., Chang C.C., and Madhukar B.V. Modulation of intercellular communication during radiation and chemical carcinogenesis. Radiat Res 123 (1990) 241-251
60. Upham B.L., Kang K.S., Cho H.Y., and Trosko J.E. Hydrogen peroxide inhibits gap junctional intercellular communication in glutathione sufficient but not glutathione deficient cells. Carcinogenesis 18 (1997) 37-42
61. Varanasi U., Chu R., Huang Q., Castellon R., Yeldandi A.V., and Reddy J.K. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 271 (1996) 2147-2155
62. Vu-Dac N., Schoonjans K., Laine B., Fruchart J.C., Auwerx J., and Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 269 (1994) 31012-31018
63. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96 (1995) 741-750
64. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Fruchart J.C., et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273 (1998) 25713-25720
65. Walgren J.E., Kurtz D.T., and McMillan J.M. Expression of PPAR(alpha) in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun Mol Pathol Pharmacol 108 (2000) 116-132
66. Woodyatt N.J., Lambe K.G., Myers K.A., Tugwood J.D., and Roberts R.A. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20 (1999) 369-372
67. Yeldandi A.V., Rao M.S., and Reddy J.K. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res 448 (2000) 159-177
68. Youssef J.A., and Badr M.Z. Aging and enhanced hepatocarcinogenicity by peroxisome proliferator-activated receptor alpha agonists. Ageing Res Rev 4 (2005) 103-118